| ABO |
P16442
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
|
Enzyme
|
|
0.427 |
0.885 |
| BTF3P11 |
|
basic transcription factor 3 pseudogene 11
|
|
|
0.519 |
0.731 |
| GTS |
|
Gilles de la Tourette syndrome
|
|
|
0.682 |
0.615 |
| IFNA1 |
P01562
|
interferon alpha 1
|
|
|
0.371 |
0.923 |
| IFNA13 |
P01562
|
interferon alpha 13
|
|
|
0.374 |
0.923 |
| IGHG3 |
P01860
|
immunoglobulin heavy constant gamma 3 (G3m marker)
|
|
|
0.513 |
0.769 |
| MAA |
|
microphthalmia or anophthalmia and associated anomalies
|
|
|
0.666 |
0.577 |
| MMP12 |
P39900
|
matrix metallopeptidase 12
|
Enzyme
|
|
0.484 |
0.885 |
| COX1 |
P00395
|
cytochrome c oxidase subunit I
|
Enzyme
|
|
0.441 |
0.885 |
| COX2 |
P00403
|
cytochrome c oxidase subunit II
|
Enzyme
|
|
0.352 |
0.962 |
| PECAM1 |
P16284
|
platelet and endothelial cell adhesion molecule 1
|
Cell adhesion
|
|
0.426 |
0.846 |
| RNASE3 |
P12724
|
ribonuclease A family member 3
|
|
|
0.490 |
0.808 |
| SAA3P |
|
serum amyloid A3, pseudogene
|
|
|
0.722 |
0.500 |
| SRY |
Q05066
|
sex determining region Y
|
Transcription factor
|
|
0.456 |
0.808 |
| ST2 |
|
suppression of tumorigenicity 2
|
|
|
0.576 |
0.692 |
| TRBV20OR9-2 |
|
T cell receptor beta variable 20/OR9-2 (non-functional)
|
|
|
0.403 |
0.923 |
| TAM |
|
Myeloproliferative syndrome, transient (transient abnormal
|
|
|
0.528 |
0.731 |
| H4C14 |
P62805
|
H4 clustered histone 14
|
|
|
0.541 |
0.692 |
| LOH19CR1 |
|
loss of heterozygosity, 19, chromosomal region 1
|
|
|
0.569 |
0.808 |
| PART1 |
|
prostate androgen-regulated transcript 1
|
|
|
0.483 |
0.885 |
| RNU1-1 |
|
RNA, U1 small nuclear 1
|
|
|
0.608 |
0.731 |
| MBL3P |
|
mannose-binding lectin family member 3, pseudogene
|
|
|
0.518 |
0.769 |
| MEG3 |
|
maternally expressed 3
|
|
|
0.471 |
0.846 |
| GAS5 |
|
growth arrest specific 5
|
|
|
0.497 |
0.808 |
| SPZ1 |
Q9BXG8
|
spermatogenic leucine zipper 1
|
|
|
0.507 |
0.769 |